亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma

医学 细胞因子释放综合征 淋巴瘤 内科学 淋巴母细胞淋巴瘤 肿瘤科 挽救疗法 存活率 嵌合抗原受体 儿科 免疫学 免疫疗法 化疗 T细胞 癌症 免疫系统
作者
Marcelo C. Pasquini,Zhen‐Huan Hu,Kevin J. Curran,Theodore W. Laetsch,Frederick L. Locke,Rayne H. Rouce,Michael A. Pulsipher,Christine L. Phillips,Amy K. Keating,Matthew J. Frigault,Dana Salzberg,Samantha Jaglowski,Joshua P. Sasine,Joseph Rosenthal,Monalisa Ghosh,Daniel J. Landsburg,Steven Margossian,Paul L. Martin,Manali Kamdar,Peiman Hematti,Sarah Nikiforow,Cameron J. Turtle,Miguel‐Angel Perales,Patricia Steinert,Mary M. Horowitz,Amy Moskop,Lida Pacaud,Lan Yi,Raghav Chawla,Eric Bleickardt,Stephan A. Grupp
出处
期刊:Blood Advances [American Society of Hematology]
卷期号:4 (21): 5414-5424 被引量:316
标识
DOI:10.1182/bloodadvances.2020003092
摘要

Abstract Tisagenlecleucel is a CD19 chimeric antigen receptor (CAR) T-cell therapy approved for treatment of pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL) and adults with non-Hodgkin lymphoma (NHL). The initial experience with tisagenlecleucel in a real-world setting from a cellular therapy registry is presented here. As of January 2020, 511 patients were enrolled from 73 centers, and 410 patients had follow-up data reported (ALL, n = 255; NHL, n = 155), with a median follow-up of 13.4 and 11.9 months for ALL and NHL, respectively. Among patients with ALL, the initial complete remission (CR) rate was 85.5%. Twelve-month duration of response (DOR), event-free survival, and overall survival (OS) rates were 60.9%, 52.4%, and 77.2%, respectively. Among adults with NHL, the best overall response rate was 61.8%, including an initial CR rate of 39.5%. Six-month DOR, progression-free survival, and OS rates were 55.3%, 38.7%, and 70.7%, respectively. Grade ≥3 cytokine release syndrome and neurotoxicity were reported in 11.6% and 7.5% of all patients, respectively. Similar outcomes were observed in patients with in-specification and out-of-specification products as a result of viability <80% (range, 61% to 79%). This first report of tisagenlecleucel in the real-world setting demonstrates outcomes with similar efficacy and improved safety compared with those seen in the pivotal trials.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
田様应助LL采纳,获得10
10秒前
16秒前
LL发布了新的文献求助10
22秒前
25秒前
么么么发布了新的文献求助10
30秒前
40秒前
么么么完成签到 ,获得积分10
51秒前
52秒前
李九妹完成签到 ,获得积分10
56秒前
经冰夏完成签到 ,获得积分10
59秒前
59秒前
科研通AI2S应助科研通管家采纳,获得10
1分钟前
科研通AI2S应助科研通管家采纳,获得10
1分钟前
大个应助含蓄戾采纳,获得10
1分钟前
轩仔发布了新的文献求助10
1分钟前
1分钟前
NCL完成签到,获得积分10
1分钟前
1分钟前
好巧完成签到,获得积分10
1分钟前
含蓄戾完成签到,获得积分10
1分钟前
1分钟前
含蓄戾发布了新的文献求助10
1分钟前
医者仁心完成签到,获得积分10
1分钟前
Julie发布了新的文献求助10
1分钟前
打打应助NCL采纳,获得10
1分钟前
搜集达人应助材料摆渡人采纳,获得10
1分钟前
1分钟前
choyng发布了新的文献求助10
1分钟前
科研通AI2S应助XIN采纳,获得10
2分钟前
热带蚂蚁完成签到 ,获得积分10
2分钟前
2分钟前
2分钟前
2分钟前
樱桃猴子应助Julie采纳,获得10
2分钟前
NCL发布了新的文献求助10
2分钟前
木木发布了新的文献求助10
2分钟前
研友_VZG7GZ应助CSun采纳,获得10
2分钟前
Jason发布了新的文献求助10
2分钟前
林非鹿完成签到,获得积分10
2分钟前
himat完成签到,获得积分10
3分钟前
高分求助中
Evolution 10000
Sustainability in Tides Chemistry 2800
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
юрские динозавры восточного забайкалья 800
English Wealden Fossils 700
Foreign Policy of the French Second Empire: A Bibliography 500
Chen Hansheng: China’s Last Romantic Revolutionary 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3146703
求助须知:如何正确求助?哪些是违规求助? 2798015
关于积分的说明 7826470
捐赠科研通 2454516
什么是DOI,文献DOI怎么找? 1306328
科研通“疑难数据库(出版商)”最低求助积分说明 627704
版权声明 601522